Table 5Unit Costs

CostsPoint estimateProbability distributionDistribution parametersSource
Intervention costs
Cost of AC operation (also cost of bladder perforation or re-augmentation)£5929Gammaκ = 3.77c
θ = 1571.25
NHS Reference
Costs 2009–201016
Cost of 100U BTX£138Assumed fixedBNF 6017
Cost of Injection of substance into bladder wall£293GammaSE = 145.14NHS Reference
Costs 2009–201016
Cost of Pads£0.25Gammaκ = 2.55
θ = 0.98
NHS Supply Chain
Catalogue 201118
Cost of Intermittent Catheter£0.75Gammaκ = 2.5
θ = 0.3
NHS Supply Chain
Catalogue 2011
Adverse event costs
Cost of treating a UTIs£36Gammaκ = 2.5
θ = 0.3
NHS Reference
Costs 2009–201016
Bladder stone removal£522Gammaκ = 7.49
θ = 69.69
NHS Reference
Costs 2009–201016
Bowel obstruction (70% 1 extra week in hospital 30% major surgical procedure)£1,251GammaWork out how to present thisNHS Reference
Costs 2009–201016
Ileus£1,381Gammaκ = 24.39
θ = 13.61
NHS Reference
Costs 2009–201016
Haematuria (GP surgery consultation lasting 11.7 min)£32Assumed fixedPSSRU 201019
Appliance Costs
Pads£0.25Gammaκ = 2.55
θ = 0.10
NHS supply chain
Catalogue 201118
Sheaths£0.79Gammaκ = 3.9
θ = 0.2
NHS Drug tariff
Bags£6.85Gammaκ = 4
θ = 1.71
NHS supply chain
Catalogue 2011
Indwelling catheter£5.31Gammaκ = 6.9
θ = 0.77
NHS supply chain
Catalogue 2011
District nurse time 30 min£32Assumed FixedPSSRU 201019
Average costs of intermittent catheters£0.75Gammaκ = 2.47
θ = 0.30
NHS supply chain
Catalogue 2011
Appliance cost Incontinent (1 cycle)£759
Appliance cost Mild incontinent (1 cycle)£1,078
Appliance cost Continent (1 cycle)£966
c

κ and θ are the parameters that describe the Gamma distribution. κ describes the shape of the distribution and θ describes the scale.

κ and θ are the parameters that describe the Gamma distribution. κ describes the shape of the distribution and θ describes the scale.

From: Appendix I, Cost-effectiveness analysis – Botulinum toxin type A versus Augmentation Cystoplasty

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.